p38 Mitogen−Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma

Asthma Clinical Trial

Official title:

p38 MAPK Activation as the Basis for Corticosteroid Insensitivity in Severe Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00676572
• Other study ID #: 08/H0708/29
• Secondary ID: CRO1014
• Status: Completed
• Start date: May 2008
• Est. completion date: October 2011

Study information

• Verified date: October 2019
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This research aims to find out how the inflammation in patients suffering from severe asthma is different from that in non−severe asthma, and how it may prevent corticosteroids from working efficiently in severe asthma.

It will look,in particular, at a protein enzyme called p38 mitogen−activated protein kinase (p38 MAPK for short)which controls the activation of several important pathways in the cell. We wish to find out whether this enzyme is more active in cells obtained from patients with severe asthma compared to those with non−severe asthma. We would like to understand how this enzyme can cause the cell to respond less well to the anti−inflammatory effects of corticosteroids. We also wish to find out whether any specific inhibitors of p38 MAPK can improve severe asthma by improving the effects of corticosteroids on these cells.

We hypothesise that activation of the intracellular MAPK signalling pathway underlies the inflammatory processes of severe asthma, and leads to the diminution of the anti-inflammatory actions of CS through histone modification.

Description:

DESIGN Comparative study to analyse differences in the characteristics of lung macrophages and blood monocytes between non-severe and severe asthmatics.

AIMS

1. To determine whether there are differences in terms of cell expression and activation between lung macrophages and blood monocytes from non-severe and severe asthma

2. To determine the mechanisms of the lung macrophage and blood monocyte relative resistance to the effect of corticosteroids in severe asthma, and particularly focus on the role of p38 MAPK

3. To determine the differences in airway smooth muscle cells between non-severe and severe asthma

OUTCOME MEASURES

1. Clinically the differences in inflammatory and remodelling markers between non-severe and severe asthma

2. Differences in histone phosphorylation, NF-kB activity and glucocorticoid receptor activation and actions in macrophages and monocytes between non- severe and severe asthma

3. Differences in behaviour of airway smooth muscle cells cultured from biopsies obtained from non-severe and severe asthma

Severe and non-severe asthmatic subjects will be classified following ATS criteria. They undergo spirometry with reversibility testing, PC20, skin prick tests, exhaled nitric oxide measurements and induced sputum. They will have blood taken for PBMCs and undergo fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: October 2011
• Est. primary completion date: October 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Age 18-60

• Physician diagnosis of asthma

Non-severe asthmatic subjects:

• mild to moderately severe asthma.

• The groups will be defined as follows, according to their need for treatments (as established in the Asthma Management GINA or BTS guidelines):

1. Mild: intermittent symptoms and need for reliever bronchodilator less than once a day

2. moderate asthma: well-controlled asthma with minimal symptoms while on inhaled corticosteroid therapy not exceeding 2,000 µg beclomethasone equivalent.

Severe asthmatic subjects:

• will have at least 1 major and 2 minor criteria (as below) Major characteristics (at least one of the following criteria)

• Treatment with continuous or near continuous (>50% of year) oral corticosteroids

• Requirement for treatment with high dose inhaled corticosteroids (ICS) Minor characteristics (at least 2 out of the following)

1. Requirement for daily treatment with a controller medication in addition to ICS e.g. LABA, theophylline, leukotriene antagonist

2. Asthma symptoms requiring SABA on a daily or near daily basis

3. Persistent airways obstruction (FEV1 <80% predicted, diurnal PEF variation >20%)

4. One or more emergency care visits for asthma per year

5. 3 or more steroid "bursts" per year

6. Prompt deterioration with = 25% reduction in oral or ICS

7. Near fatal asthma event in the past

Exclusion Criteria:

• Current smokers, or less than 3 years since quitting smoking (< 5 pack/years)

• Less than 4 weeks from an exacerbation

• On steroid-sparing agent or immunosuppressant such as azathioprine, methotrexate and ciclosporin

• Concomitant anti-IgE therapy

• On anti-platelet or anti-coagulant drugs

• Low platelet count

• Pregnancy or breast-feeding

• Intubation for asthma within 6 months of entry into this study (if undergoing bronchoscopy)

Related Conditions & MeSH terms

• Asthma

Intervention

Other:
• Fiberoptic bronchoscopy; blood test
Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells

Locations

Country	Name	City	State
United Kingdom	Asthma Laboratory, Royal Brompton Hospital, Sydney Street	London

Sponsors (3)

Lead Sponsor	Collaborator
Imperial College London	Medical Research Council, Royal Brompton & Harefield NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Bhavsar P, Khorasani N, Hew M, Johnson M, Chung KF. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J. 2010 Apr;35(4):750-6. doi: 10.1183/09031936.00071309. Epub 2009 Oct 19. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Differences in Activity and Downstream Activity of the p38 MAPK Activity in Macrophages or PBMCs Between Those From Severe and Non-Severe Asthmatics		3 years
Secondary	Differences in the Effect of p38 MAPK Inhibitor in Dexamethasone-Inhibition of Cytokine Release From Alveolar Macrophages and PBMCs Between Severe and Non-Severe Asthmatics	Percentage of Suppression of IL6 release by p38 MAPK inhibitor	3 years